Case ascertainment and estimated incidence of drug-induced long-QT syndrome: Study in Southwest France

British Journal of Clinical Pharmacology

Volumn 66, Issue 3, 2008, Pages 386-395

  Molokhia, Mariam ^a   Pathak, Atul ^b   Lapeyre Mestre, Maryse ^b   Caturla, Laetitia ^b   Montastruc, Jean Louis ^b   McKeigue, Paul ^c  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^b TOULOUSE UNIVERSITY HOSPITAL   (France)

^c UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

Arrhythmia; Genetics; Long QT syndrome; Pharmacoepidemiology; Torsade de pointes

Indexed keywords

ALIMEMAZINE; AMIODARONE; AMISULPRIDE; ANTIARRHYTHMIC AGENT; ANTIBIOTIC AGENT; ATENOLOL; BENAZEPRIL PLUS HYDROCHLOROTHIAZIDE; BENZODIAZEPINE; BEPRIDIL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; BRIMONIDINE; CELECOXIB; DIGOXIN; FLECAINIDE; FLUVOXAMINE; FUROSEMIDE; ITRACONAZOLE; LOMEFLOXACIN; NEUROLEPTIC AGENT; PERICIAZINE; QUINIDINE; SOTALOL; THIORIDAZINE; URAPIDIL; VALPROIC ACID; VINCAMINE;

ADULT; AGED; ARTICLE; DRUG INDUCED DISEASE; DRUG SURVEILLANCE PROGRAM; FEMALE; FRANCE; GENETIC SUSCEPTIBILITY; HEART VENTRICLE EXTRASYSTOLE; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE TACHYCARDIA; HIGH RISK POPULATION; HUMAN; INCIDENCE; LONG QT SYNDROME; MAJOR CLINICAL STUDY; MALE; POLYMORPHIC VENTRICULAR TACHYCARDIA; PREVALENCE; PRIORITY JOURNAL; QT PROLONGATION; SUDDEN DEATH; SYNCOPE; TORSADE DES POINTES;

ADULT; AGED; AGED, 80 AND OVER; ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; DEATH, SUDDEN, CARDIAC; ELECTROCARDIOGRAPHY; FEASIBILITY STUDIES; FEMALE; FRANCE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INCIDENCE; LONG QT SYNDROME; MALE; MIDDLE AGED; POTASSIUM CHANNELS; RETROSPECTIVE STUDIES; RISK FACTORS; TORSADES DE POINTES;

EID: 49549124256     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2008.03229.x     Document Type: Article

References (21)

1. Shah RR. Pharmacogenetic aspects of drug-induced torsade de pointes: potential tool for improving clinical drug development and prescribing. Drug Saf 2004 27 : 145 72.
2. Reilly JG, Ayis SA, Ferrier IN, Jones SJ, Thomas SHQ. Tc-interval abnormalities and psychotropic drug therapy in psychiatric patients. Lancet 2000 355 : 1048 52.
3. Reilly JG, Ayis SA, Ferrier IN, Jones SJ, Thomas SH. Thioridazine and sudden unexplained death in psychiatric in-patients. Br J Psychiatry 2002 180 : 515 22.
4. Hanrahan JP, Choo PW, Carlson W, Greineder D, Faich GA, Platt R. Terfenadine-associated ventricular arrhythmias and QTc interval prolongation. A retrospective cohort comparison with other antihistamines among members of a health maintenance organization. Ann Epidemiol 1995 5 : 201 9.
5. De Bruin ML, Pettersson M, Meyboom RH, Hoes AW, Leufkens HG. Anti-HERG activity and the risk of drug-induced arrhythmias and sudden death. Eur Heart J 2005 26 : 590 7.
6. Committee for Proprietary Medicinal Products (CPMP). Points to Consider: the Assessment for the Potential for QT Interval Prolongation by Non-Cardiovascular Medicinal Products. London : European Agency for the Evaluation of Medicinal Products, 1997.
7. Committee for Proprietary Medicinal Products (CPMP). Notes for Guidance on Safety Pharmacologic Studies for Assessing the Potential for Delayed Ventricular Repolarization (QT Interval Prolongation) by Human Pharmaceuticals. London : European Agency for the Evaluation of Medicinal Products, 2002.
8. Straus SM, Sturkenboom MC, Bleumink GS, Dieleman JP, van der LJ, de Graeff PA, Kingma JH, Stricker BH. Non-cardiac QTc-prolonging drugs and the risk of sudden cardiac death. Eur Heart J 2005 26 : 2007 12.
9. De Bruin ML, van Puijenbroek EP, Bracke M, Hoes AW, Leufkens HG. Pharmacogenetics of drug-induced arrhythmias: a feasibility study using spontaneous adverse drug reactions reporting data. Pharmacoepidemiol Drug Saf 2006 15 : 99 105.
10. James AF, Choisy SC, Hancox JC. Recent advances in understanding sex differences in cardiac repolarization. Prog Biophys Mol Biol 2007 94 : 265 319.
11. Darpo B. Spectrum of drugs prolonging QT interval and the incidence of torsade de pointes. Eur Heart J 2001 3 (Suppl. K 70 80.
12. Bongard V, Marc D, Philippe V, Jean-Louis M, Maryse LM. Incidence rate of adverse drug reactions during long-term follow-up of patients newly treated with amiodarone. Am J Ther 2006 13 : 315 9.
13. Bateman DN, Good AM, Afshari R, Kelly CA. Effects of licence change on prescribing and poisons enquiries for antipsychotic agents in England and Scotland. Br J Clin Pharmacol 2003 55 : 596 603.
14. Gasquet I, Negre-Pages L, Fourrier A, Nachbaur G, El-Hasnaoui A, Kovess V, Lepine JP Psychotropic drug use and mental psychiatric disorders in France; results of the general population ESEMeD/MHEDEA 2000 epidemiological study Encephale 2005 31 : 195 206.
15. Barbey JT, Lazzara R, Zipes DP. Spontaneous adverse event reports of serious ventricular arrhythmias, QT prolongation, syncope, and sudden death in patients treated with cisapride. J Cardiovasc Pharmacol Ther 2002 7 : 65 76.
16. Camm AJ. The design and conduct of human studies to detect and quantify QT interval prolongation induced by new chemical entities. Fundam Clin Pharmacol 2002 16 : 141 5.
17. Mohler PJ, Schott JJ, Gramolini AO, Dilly KW, Guatimosim S, duBell WH, Song LS, Haurogne K, Kyndt F, Ali ME, Rogers TB, Lederer WJ, Escande D, Le MH, Bennett V. Ankyrin-B mutation causes type 4 long-QT cardiac arrhythmia and sudden cardiac death. Nature 2003 421 : 634 9.
18. Splawksi. OMIM 2004. Available at http://www.ncbi.nlm.nih.gov/entrez/ dispomim.cgi?id=600919 (last accessed 8 April 2008).
19. Tawil R, Ptacek LJ, Pavlakis SG, DeVivo DC, Penn AS, Ozdemir C, Griggs RC. Andersen's syndrome: potassium-sensitive periodic paralysis, ventricular ectopy, and dysmorphic features. Ann Neurol 1994 35 : 326 30.
20. Paulussen AD, Gilissen RA, Armstrong M, Doevendans PA, Verhasselt P, Smeets HJ, Schulze-Bahr E, Haverkamp W, Breithardt G, Cohen N, Aerssens J. Genetic variations of KCNQ1, KCNH2, SCN5A, KCNE1, and KCNE2 in drug-induced long QT syndrome patients. J Mol Med 2004 82 : 182 8.
21. Yang P, Kanki H, Drolet B, Yang T, Wei J, Viswanathan PC, Hohnloser SH, Shimizu W, Schwartz PJ, Stanton M, Murray KT, Norris K, George AL Jr., Roden DM. Allelic variants in long-QT disease genes in patients with drug-associated torsades de pointes. Circulation 2002 105 : 1943 8.